Andere talen NextCure, Inc.

Aandelen

NXTC

US65343E1082

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,44 ^USD	-5,88%		-4,64%	+26,32%

08/04	NextCure, Inc. en LigaChem Biosciences, Inc. presenteren preklinische gegevens over B7-H4 antilichaam geneesmiddelconjugaat op AACR 2024	CI
04/04	NextCure, Inc. benoemt Rakesh Dixit tot lid van de wetenschappelijke adviesraad	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024	24/04
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024	08/04
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board	04/04
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board	04/04
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference	02/04
NextCure : March 2024 Corporate Presentation	21/03
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
NextCure Provides Business Update and Reports Full Year 2023 Financial Results	21/03
North American Morning Briefing : Markets on Hold -2-	20/03
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	05/03
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	05/03
Top Premarket Decliners	27/02
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	18/01
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	18/01
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
NextCure Provides Year-End Clinical Pipeline Updates	14/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NextCure, Inc.

Aandelen

NXTC

US65343E1082

Andere talen

Filters